The role of immune reconstitution in cytomegalovirus infection

BioDrugs

Volumn 16, Issue 2, 2002, Pages 89-95

  Weinberg, Adriana ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; CD4 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; RECOMBINANT INTERLEUKIN 12; RECOMBINANT INTERLEUKIN 2; VIRUS VACCINE;

ADOPTIVE TRANSFER; CELLULAR IMMUNITY; CYTOMEGALOVIRUS INFECTION; CYTOTOXIC T LYMPHOCYTE; HELPER CELL; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNITY; IMMUNOMODULATION; IMMUNOPATHOGENESIS; LYMPHOCYTE FUNCTION; LYMPHOCYTE SUBPOPULATION; MORBIDITY; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0036096772     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-200216020-00002     Document Type: Review

References (90)

1. Virologic studies on cytomegalic inclusion disease
2. Complement-fixing antibodies against cytomegalovirus in different parts of the world
3. Cytomegalovirus infection in sexually active adolescents
4. Infectious-mononucleosis-like disease with negative heterophil agglutination test: Clinical features in relation to Epstein-Barr virus and cytomegalovirus antibodies
5. Cytomegalovirus infection in patients with AIDS
6. Impact of cytomegalovirus infection on organ transplant recipients
7. New strategies for prevention and therapy of cytomegalovirus infection and disease in solid-organ transplant recipients
8. Nonbacterial pneumonia after allogeneic marrow transplantation. A review of ten years' experience
9. Infections complicating congenital immunodeficiency syndromes
10. Summary of a workshop on surveillance for congenital cytomegalovirus disease
11. Reactivation of latent human cytomegalovirus by allogeneic stimulation of blood cells from healthy donors
12. Molecular mimicry by cytomegalovirus-encoded homologues of G protein coupled receptors, MHC class I heavy chains and chemokines
13. Human cytomegalovirus induces interleukin-8 production by a human monocytic cell line, THP-1, through acting concurrently on AP-1 and NF-κB-Binding sites of the interleukin-8 gene
14. Cytomegalovirus-infected endothelial cells recruit neutrophils by the secretion of C-X-C chemokines and transmit virus by direct neutrophil-endothelial cell contact and during neutrophil transendothelial migration
15. Cytomegalovirus induced up-regulation of LFA-3 (CD58) and ICAM-1 (CD54) is a direct viral effect that is not prevented by ganciclovir or foscarnet treatment
16. Symptomatic cytomegalovirus infection in seropositive kidney recipients: Reinfection with donor virus rather than reactivation of recipient virus
17. Intrauterine transmission of cytomegalovirus to infants of women with preconceptional immunity
18. Cytomegalovirus reactivation and tumor necrosis factor
19. Adoptive transfer studies demonstrating the antiviral effect of natural killer cells in vivo
20. Comparative virulence and immunogenicity of the Towne strain vaccine and a nonattenuated strain of cytomegalovirus
21. Cytomegalovirus-encoded β chemokine promotes monocyte-associated viremia in the host
22. Human cytomegalovirus US2 destabilizes major histocompatibility complex class I heavy chains
23. Cytomegalovirus US2 destroys two components of the MHC class II pathway, preventing recognition by CD4+ T cells
24. A ribonucleotide reductase homolog of cytomegalovirus and endothelial cell tropism
25. Cytotoxic T cells in cytomegalovirus infection: HLA-restricted T lymphocyte and non-T lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus in bone marrow transplant recipients
26. Importance of cytotoxic lymphocytes during cytomegalovirus infection in renal transplant recipients
27. Interstitial murine cytomegalovirus pneumonia after irradiation: Characterization of cells that limit viral replication during established infection of the lungs
28. Induction of complement dependent and independent neutralizing antibodies by recombinant derived human cytomegalovirus gp155-166 (gB)
29. The role of natural killer cells and antibody dependent cell-mediated cytotoxicity during murine cytomegalovirus infection
30. Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients
31. Intravenous immune globulin for prevention of cytomegalovirus infection and interstitial pneumonia after bone marrow transplantation
32. Effect of passive antibody on congenital cytomegalovirus infection in guinea pigs
33. Risk factors for cytomegalovirus infection after human marrow transplantation
34. Increased incidence of late CMV disease in allogeneic marrow transplant recipients after ganciclovir prophylaxis is due to a lack of CMV-specific T cell responses
35. CMV infection after organ transplantation: Immunopathological and clinical aspects
36. A multivariate analysis of risk factors for cytomegalovirus infection in liver transplant recipients
37. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease
38. Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine and ritonavir: Results of AIDS clinical trials group protocol 315
39. Immune reconstitution in the first year of potent antiretroviral therapy and its relationship to virologic response
40. Long lasting remission of cytomegalovirus retinitis without maintenance therapy in human immunodeficiency virus-infected patients
41. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
42. Immune recovery vitritis associated with inactive CMV retinitis; a new syndrome
43. Pathogenesis of CMV immune recovery uveitis
44. Cytomegalovirus infection and specific cell-mediated immunity after marrow transplant
45. Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: Pattern of recovery and correlation with cytomegalovirus infection and disease
46. Comparison of immune reconstitution after unrelated and related T-cell-depleted bone marrow transplantation: Effect of patient age and donor leukocyte infusions
47. Cytomegalovirus (CMV)-specific T cell immunity after renal transplantation mediates protection from CMV disease by limiting the systemic virus load
48. Expression of granzyme B during primary cytomegalovirus infection after renal transplantation
49. Recovery from cytomegalovirus infection is associated with activation of peripheral blood lymphocytes
50. Risk of developing cytomegalovirus retinitis in persons infected with the human immunodeficiency virus
51. Recurrences of cytomegalovirus retinitis in a human immunodeficiency virus-infected patient, despite potent antiretroviral therapy and apparent immune reconstitution
52. Loss of cytomegalovirus-specific CD4+ T cell responses in human immunodeficiency virus type 1-infected patients with high CD4+ T cell counts and recurrent retinitis
53. Inconsistent reconstitution of cytomegalovirus-specific cell-mediated immunity in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy
54. Preconception immunization with a cytomegalovirus (CMV) glycoprotein vaccine improves pregnancy outcome in a guinea pig model of congenital CMV infection
55. Kinetics of the antibody response against human cytomegalovirus-specific proteins in allogeneic bone marrow transplant recipients
56. Neutralizing antibody response against human cytomegalovirus in allogeneic bone marrow-transplant recipients
57. Delayed acquisition of high-avidity anti-cytomegalovirus antibody is correlated with prolonged antigenemia in solid organ transplant recipients
58. Prevalence of resistance in patients receiving ganciclovir for serious cytomegalovirus infection
59. Isolation of foscarnet-resistant human cytomegalovirus patterns of resistance and sensitivity to other antiviral drugs
60. Ganciclovir
61. Protection against lethal cytomegalovirus infection by a recombinant vaccine containing a single nonameric T-cell epitope
62. CD-8 positive cytotoxic T lymphocytes specific for murine cytomegalovirus immediate-early antigens mediate protective immunity
63. Cytotoxic T cells specific for cytomegalovirus: A potential therapy for immunocompromised patients
64. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor
65. Prophylactic immunoglobulin therapy improves the outcome of renal transplantation in recipients at risk for primary cytomegalovirus disease
66. Prospective randomized trial of efficacy of ganciclovir versus that of anti-cytomegalovirus (CMV) immunoglobulin to prevent CMV disease in CMV-seropositive heart transplant recipients treated with OKT3
67. Cytomegalovirus immune globulin prophylaxis in liver transplantation: A randomized, double-blind placebo controlled trial
68. Prevention of cytomegalovirus-associated diseases with immunoglobulin
69. Ganciclovir/immunoglobulin combination therapy for the treatment of human cytomegalovirus-associated interstitial pneumonia in bone marrow allograft recipients
70. Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants
71. Cytomegalovirus pneumonia after bone marrow transplantation successfully treated with the combination of ganciclovir and high-dose intravenous immune globulin
72. Immune globulin versus antivirals versus combination for prevention of cytomegalovirus disease in transplant recipients
73. A randomized trial of high dose polyvalent intravenous immunoglobulin (HDIgG) vs. cytomegalovirus (CMV) hyperimmune IgG in allogeneic hemopoietic stem cell transplants (HSCT)
74. Biology and therapeutic uses of myeloid hematopoietic growth factors and interferons
75. The interfeons: Mechanism of action and clinical applications
76. Effects of interferon-alpha on cytomegalovirus reactivation syndromes in renal-transplant recipients
77. Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus
78. Outpatient continuous intravenous interleukin-2 or subcutaneous, polyethylene glycol-modified interleukin-2 in human immunodeficiency virus-infected patients: A randomized, controlled, multicenter study
79. Filgrastim restores interleukin-2 production in blood from patients with advanced human immunodeficiency virus infection
80. A randomized, placebo-controlled trial of granulocyte-macrophage colony-stimulating factor and nucleoside analogue therapy in AIDS
81. Clinical trials of immunization with the Towne 125 strain of human cytomegalovirus
82. Specific cellular and humoral immunity after immunization with live Towne strain cytomegalovirus vaccine
83. Effect of Towne live virus vaccine on cytomegalovirus disease after renal transplant
84. Immunity induced by primary human cytomegalovirus infection protects against secondary infection among women of childbearing age
85. A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant
86. Effects of antigen dose and immunization regimens on antibody responses to a cytomegalovirus glycoprotein B subunit vaccine
87. The safety and use of canarypox vectored vaccines
88. Preclinical evaluation of an ALVAC (canarypox)-human cytomegalovirus glycoprotein B vaccine candidate
89. Development of a cytomegalovirus vaccine: Lessons from recent clinical trials
90. Protective antiviral cytotoxic T cell memory is most efficiently maintained by restimulation via dendritic cells